Trials / Terminated
TerminatedNCT02756728
A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma
A Randomized Phase I/II Study of BI-505 in Conjunction With High-dose Melphalan and Autologous Stem Cell Transplantation for Multiple Myeloma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- BioInvent International AB · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the safety and efficacy of administering BI-505 in conjunction with high dose melphalan and stem cell transplantation in multiple myeloma patients.
Detailed description
N/A study is closed
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BI-505 | Treatment with BI-505 10 mg/kg bi-weekly infusion, up to 9 doses over 4 months |
| OTHER | High dose melphalan | High dose melphalan (HDM) |
| OTHER | Autologous stem cell transplantation | Autologous stem cell transplantation (ASCT) |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2016-04-29
- Last updated
- 2020-03-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02756728. Inclusion in this directory is not an endorsement.